Advances in detecting cancer recurrence uh earlier and uh more accurately are transforming how the disease is treated and monitored. One of the companies on the leading edge is Nera. Joining us now, Nera CEO Steve Chapman.The company is celebrating 10 years since going public on the NASDAQ and you got a a real market cap uh at this point and some really good um not only peer-reviewed research, you've got a product. Uh I think you were cash did you have a profit or at least cash flow positive at this point. ...

GeneDx (WGS) 2025 Conference June 04, 2025 09:55 AM ET Speaker0 Good. Good morning. I'm Tycho Peterson from the Life Science Tools Diagnostics team. It's my pleasure to introduce our next company this morning, GeneDx. Before we jump into Q and A, going turn it over to Katherine to introduce some media. Speaker1 Wonderful. Well, thank you so much, Tycho. Thank you to the entire Jefferies team. Coming out of another busy ASCO news cycle, I'm happy to turn everyone's attention to another really important area ...

Natera (NASDAQ: NTRA ) is a genetic testing company, with focuses on oncology, women's health, and organ health. Their signature product, Signatera, can help predict the efficacy of many forms of cancer treatment. Natera has alsoLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and ...

Castle Biosciences celebrates an incredible milestone — the 200,000th order of the DecisionDx-Melanoma test! This milestone is so much more than a number: it represents 200,000 opportunities to provide clinicians and their patients with more accurate, more personalized insights that help guide their treatment plan decisions in melanoma care. With every test, we're empowering health care professionals to make more informed and more precise decisions that can fundamentally transform lives.Castle founder, pres ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - CFO Conference Call Participants David Westenberg - Piper Sandler Lu Li - UBS Andrew Cooper - Raymond James Operator Greetings, and welcome to the Fulgent Genetics, Inc. Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question and answer ...